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The Pattern of Interleukin-1/3 (IL-1/3) and Its Modulating Agents IL-1 
Receptor Antagonist and IL-1 Soluble Receptor Type II in Acute 
Meningococcal Infections
By Marcel van Deuren, Johanna van der Ven-Jongekrijg, Edouard Vannier, Roelof van Dalen, Gerard Pesman,
Anton K.M. Bartelink, Charles A. Dinarello, and Jos W.M. van der Meer
lnterleukin-1/3 (IL-1 fi) is considered an important mediator 
in the pathogenesis of septic shock or bacterial meningitis. 
Its activity is specifically modulated by IL-1 receptor antago­
nist (IL-1 Ra) and IL-1 soluble receptor type II (IL-1 sRII). We 
now describe the time-course of IL-1/3 and these modulating 
agents in 59 patients with acute meningococcal infections, 
the prototype human disease of acute endotoxin exposure. 
Plasma IL-1 fi was increased only in severe shock and normal­
ized within 12 to 24 hours, indicating that patients were 
admitted in an early stage of cytokine activation. Increased 
IL-1/3 values in cerebrospinal fluid (CSF) were confined to 
patients with meningitis. Plasma IL-IRa was elevated in both 
shock and nonshock patients, extremely high values being 
measured in severe shock. High concentrations of IL-1Ra in 
CSF were found in meningitis. Plasma IL-1Ra peaked shortly 
after IL-1 fi and decreased steeply in 1 to 2 days, followed 
by sustained moderately elevated levels in shock patients. 
Interestingly, IL-1 sRII showed a completely different pattern.
ACU TE M EN IN G O CO CCA L infections are the prototype 
i T \. disease of overwhelming endotoxin exposure in hu­
mans and are characterized by a generalized activation of 
the cytokine network.1 High plasma concentrations of endo­
toxin and proinflammatory cytokines such as tumor necrosis 
factor-a (TNF-cv) and interleukin-\j3 (IL-1 ¡3) correlate well 
with the severity of shock, whereas in meningitis elevated 
concentrations are found in cerebrospinal fluid (CSF).1'* Pro- 
inflammatory cytokines are modulated by an early activation 
of antiinflammatory cytokines, including IL-1 receptor an­
tagonist (IL-IRa), IL-6, and IL-10.1,12 Further modulation 
takes place at cytokine receptor level by regulation of recep­
tor density on target cells and the presence of soluble recep­
tors.1,12'14 As such, we previously reported that in severe 
shock, TNF soluble receptors are increased and IL-6 soluble 
receptors (IL-6sR) are decreased, resulting in less activity 
for both ligand cytokines.9,12,14
The regulation of IL-1 activity is presumably more com­
plex. The proinfiammatory effects of IL-1 are mediated by 
IL-1 a  that remains mainly cell-associated and by IL-1 (3 that 
is mostly released. These effects are restrained by IL-IRa, a 
peptide that binds to IL-1 receptors (IL-1R) but lacks agonist 
activity.1'' IL-1 a  is undetectable in plasma of patients with 
meningococcal infections, whereas plasma IL-1 (3 is in­
creased only in patients with severe shock.1,4,12 Plasma IL- 
IRa is elevated in all patients with meningococcal infections 
but extremely high values are found during severe shock.1,12 
IL-1 activity is also modulated by the density of cell-bound 
IL-1R and the presence of IL-lsR, generated by cleavage of 
the extracellular domain of IL-1 R: Two types of IL-1 R exist: 
IL-1R type I (IL-1RI), predominately expressed on the sur­
face of T cells and fibroblasts with IL-1 a, IL-1/?, and IL- 
IRa as ligands, and IL-1R type II (IL-1RII) primarily ex­
pressed on the surface of B cells and monocytes with IL-1/3 
and, to a lesser extent, IL-IRa as ligands.16,17Transmission 
of IL-1 signals occurs via IL-1RI whereas IL-1RII functions
c
At admission, both nonshock and shock patients manifested 
a similar moderate increase of plasma IL-1 sRII. However, 
during recovery plasma IL-1 sRII further increased reaching 
maximal concentrations 3 to 5 days after admission, 1 to 2 
days after normalization of IL-1Ra. In shock patients this 
increase was more prominent than in nonshock patients. It 
is hypothesized that this increase in plasma IL-1 sRII can be 
explained by a synergistic effect of dexamethasone and en­
dotoxin. A second interesting observation was that, unlike 
the pattern in plasma, IL-1 sRII levels in CSF paralleled those 
of IL-1/3 and IL-1Ra. This suggests different modulation of 
IL-1/3 activity in the subarachnoid space and the plasma com­
partment. We conclude that: (1) During the early stage of 
meningococcal infections IL-1Ra modulates IL-1 activity, 
whereas during recovery IL-1 sRII may be more important. 
(2) Modulation in CSF and in the plasma compartment are 
differentially regulated.
© 1997 by The American Society of Hematology.
merely as tkdecoy” receptor.18'20 Cell-bound IL-1RI and IL- 
lsRI bind IL-1 a:, IL-1 ¡3, and IL-IRa with approximately 
similar kinetic constants. However, IL-lsRII preferentially 
binds IL-1 ¡3 but has lost its affinity to IL-IRa a 2,000-fold.21'24 
Thus, the presence of IL-1 soluble receptors modulates IL-1 
activity.23*25 Reportedly, plasma IL-lsRII is increased during 
sepsis.2'1 To date, no information is available on the relative 
contribution of IL-IRa and IL-lsRII to the modulation of 
IL-1 activity during severe human infections.
The present study describes the pattern of these com­
pounds in plasma and CSF of patients with acute life-threat­
ening meningococcal infections at admission and the time 
course in plasma during the first week of recovery.
MATERIALS AND METHODS
From November 1990 to March 1996, 65 patients with bacterio- 
logically proven acute meningococcal meningitis or shock were re­
ferred to the intensive care unit (ICU) of the University Hospital 
Nijmegen, The Netherlands, within 12 hours after their first hospital 
admission. From 54 of these patients, one or more serum or plasma
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Table 1. Demographic and Prognostically Relevant Clinical and Laboratory Parameters
Group A 
Meningitis Without Shock
Group B 
Meningitis With Shock
Group C 
Shock Without Meningitis
No. female/male 14/12 7/6 6/14
Age, yr 14 (1-64) 5 (0-21) 3* (0-30)
Duration of disease before admission, h 24.0 (12.5-84) 14.0§ (3.0-30) 12.011 (2.8-16.5)
Leukocytes in CSF, x 10C/L 12,300 (>100-70,000) 43411 (101-19,100) 151111 (1-98)
Peripheral leukocytes*, x 109/L 19.5 (10.5-29.9) 11.4§ (2.4-26.8) 3.8|| (1.4-13.6)
Platelets*, x 109/L 158 (51-388) 70* (39-325) 47|| (16-171)
Fibrinogen*, mg/L 5,200 (3,500-12,000) 2,400|| (230-4,115) 1,183|| (90-3,732)
Lactatet, /ymol/L 2,123 (409-4,070) 3,412* (1,806-7,013) 5,108|| (1,529-14,087)
No. of fatalities 2 (8%) 1 (8%) 6 (30%)
Medians are shown, range between brackets.
Abbreviation: CSF, cerebrospinal fluid.
Nadir* or maximum measured within the first 12 hours after admission. 
M ax im um t measured within the first 12 hours after admission. 
Compared to group A:
* P <  .05.
§ P < .01.
|| P < .001.
Compared to group B:
1i P < .001.
samples were obtained at admission and at later time points. Five 
patients admitted to the ICU of the Eemland Hospital Amersfoort, 
The Netherlands, were sampled in a similar fashion.
Blood sampling in these 59 patients started median 2.6 hours 
(range, 0.0 to 14.2) after first hospital admission. The cytokine 
plasma concentrations at admission of 36 of these patients were 
reported before.12 From 45 patients, more than one sample was drawn 
at different time points. In 39 of them, daily samples from admission 
to death or recovery up to 7 days were drawn. A CSF sample 
obtained directly alter admission was available from 25 patients.
Patients were prospectively classified in 3 groups, suffering from 
meningitis (group A, n = 26), meningitis and shock (group B, n = 
13). or shock without meningitis (group C, n = 20). According to 
Halstensen et aí,27 and as reported by us previously, outcome differs 
clearly among these groups, with mortality rates of 1.3%, 7.4%, and 
28.6% in groups A through C, respectively. Meningitis was defined 
as the presence of nuchal rigidity or a CSF leukocyte count >  100
X  10f’/L. Shock was defined as the presence of systolic hypotension 
occurring within the first 12 hours after admission that was refractory 
to a fluid bolus and required inotropics or vasopressors. In infants 
younger than 4 years the systolic blood pressure had to be <  75 
nun Hg, in children between 4 and 14 years <  85 mm Hg, and in 
patients older than 14 years <  100 mm Hg.12,27'21'Table 1 shows 
the demographic and prognostically relevant characteristics, such as 
gender, age, duration of disease before admission, leukocyte count 
in CSF, the nadir within the first 12 hours of peripheral leukocytes, 
platelets, and fibrinogen and the maximal serum lactate concentra­
tion.
All patients were treated with appropriate antibiotics and 57 re­
ceived also steroids in a dosage equivalent to 0.6 mg/kg/d dexameth- 
asone during 3 days. O f the 33 shock patients, 23 were treated with 
plasma exchange or whole blood exchange (PEBE) during the first 
24 or 48 hours, as described before.3"
In total, 9 patients died: 2 patients of group A died because of
Table 2. Admission Values of IL-1/3, IL-1Ra, and IL-1 sRII in Plasma and CSF
Group A 
Meningitis Without Shock
Group B 
Meningitis With Shock
Group C 
Shock Without Meningitis
IL-1/3
Plasma concentration, pg/mL 55 «40-135)
1
70 (<40-250) 140t (<40-2,500)
CSF concentration, pg/mL 1,750 (<400-2,850) 490 (65-3,150) 67.5* (<40-1,550)
IL-IRa
Plasma concentration, pg/mL 6,750 (2,000-30,000) 10,600 (5,100-390,000) 145,000*§ (6,480-805,000)
CSF concentration, pg/mL 26,500 (920-140,000) 5,500 (<600-140,000) 1,800* (<600-6,800)
Soluble IL-1RII
Plasma concentration, ng/mL 23.9 (17.9-57.9) 29.5 (18-57.1) 22.7 (15.8-51.2)
CSF concentration, ng/mL 36.3 (7.0-160.4) 9.1 (<2.5-58.0) 3.1* (<2.5-3.8)
Median values are shown, range between brackets. 
Compared to group A:
* P <  .05. 
t P< .01.
* P <  .001.
Compared to group B:
§ P <  .05.
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Fig 1. Plasma and CSF concentrations of interleukin-1/3 (IL-1 f i) ,  
IL-1 receptor antagonist (IL-1 Ra), and IL-1 soluble receptor type II 
(IL-1 sRII), in patients with meningococcal meningitis without shock 
(group A), meningitis with shock (group B), or shock without menin­
gitis (group C). The left panel shows the maximal plasma concentra­
tion at the day of admission of IL-1/3 and IL-1Ra, and the first mea­
sured value of IL-lsRII. The right panel shows the CSF concentrations. 
Horizontal lines indicate medians; crosses refer to patients who died.
cerebral herniation 2.5 hours after primary admission, 6 patients of 
group C died because of intractable shock after median 16.3 hours 
(range, 2.5 to 28), and 1 patient of group B died after 100 hours 
when treatment was stopped because of renal failure, severe meta­
bolic acidosis, and mutilating limb gangrene. Among the 50 survi­
vors, 2 patients of group A suffered from sensorineural deafness 
and 7 patients of groups B and C had serious ischemic sequaelae 
necessitating extensive plastic surgery.
IL-1/? and IL-IRa were measured by radioimmunoassays (RIA) as 
described previously.11 IL-1/? and IL-IRa showed no cross-reaction. 
However, IL-lsRII at higher concentrations (>  100 ng/mL) inter­
fered with the IL-1 /? assay, by capturing labeled IL-1/?. As a conse­
quence, IL-1/? concentrations were slightly overestimated when IL- 
IsRII concentrations were above 100 ng/mL. For IL-1/?, 100-^/L 
sample was used, resulting in a lower detection limit of 40 pg/mL 
and an upper limit of 2,500 pg/mL. High (CSF) samples were prop­
erly diluted. The mean IL-1/? plasma concentration ± SD in 143 
healthy controls was 55 ± 18 pg/mL. The normal IL-1 (3 concentra­
tion in CSF (n = 8) was 76 ± 10 pg/mL. The IL-IRa assay lacked 
parallelity.12 therefore a fixed amount of 10 /jL was used for all 
assays. Concentrations exceeding the upper detection limit of 25,000 
pg/mL are estimates based on measurements in further diluted sam­
ples. Normal plasma and CSF concentrations fell below the detection 
limit of the assay (<  600 pg/mL). IL-lsRII was measured by a 
specific R IA  similar to that for IL-1/? and IL-IRa. For the assay, 
25-pL sample was used, giving a detection range of 2.5 to 320 ng/ 
mL. With this assay, values in serum appeared to be reproducibly 
higher than plasma values, thus IL-lsRII data obtained in serum
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Fig 2. Time-course of the plasma concentration of IL-1 f i ,  ex­
pressed as box-plots, in patients with meningococcal meningitis 
without shock (group A), meningitis plus shock (group B), or shock 
without meningitis (group C). The gray band indicates the normal 
range of IL-1 p  (mean ± 2  x SD).
1104 VAN DEUREN ET AL
IL-1 Ra (pg/mL)
6 IL-1 Ra (pg/mL)
IL-1 Ra (pg/mL)
192
time after admission (h)
Fig 3. Individual time-course of plasma IL-1Ra concentration, in 
patients with meningococcal meningitis without shock (group A), 
meningitis plus shock (group B), and shock without meningitis 
(group C). Values >  25,000 pg/mL, indicated with an open marker, 
are estimates based on diluted samples.
were corrected according to the following formula: plasma value =
0.775 x serum value + 3 .17 (formula calculated from 29 paired 
serum and plasma samples (/• = .9951). Normal values of IL-lsRII 
were for plasma (n = 36) 16.5 ± 2.8 ng/mL and for CSF (n = 9) 
<  2.5 ng/mL.
Statistical comparison between groups was performed with analy­
sis of variance and Dunn's test or two-sided Fisher’s exact test.
RESULTS
The plasma and CSF admission values, ie, the maximum 
value of IL-l/? and IL-IRa during the day of admission (vide
infra), and the first value of IL-lsRII, are shown in Fig l 
and Table 2.
Increased plasma IL-l/? concentrations, defined as >  9 1 
pg/mL (mean plus 2 X SD of healthy controls) were found 
in 17 out of the 33 (51%) group B and C patients, all with 
very profound shock, among them 6 of the 7 fatalities. In 8 
of the 10 shock patients (80%) with increased IL-1 ¡3 values 
and more than one sample within the first 6 hours, IL-1 (3 
decreased rapidly, whereas in 2 (20%) a short-lasting in­
crease occurred. After 12 to 24 hours, plasma IL-1 [3 levels 
reached a stable level in all patients. PEBE did not affect 
the course of IL-1 ¡3. During recovery, the median IL-1/? 
plasma concentrations in groups B and C increased some­
what, with a maximum of 97.5 pg/mL (median) on day 5 in 
group B and 95.0 pg/mL on day 4 in group C (Fig 2). IL- 
\(3 in CSF of groups A. B, and C showed a reciprocal pattern, 
with the highest values in meningitis patients of group A. 
and the lowest values in patients with shock without menin­
gitis of group C.
Plasma IL-IRa concentrations were increased at admis­
sion in all patients but an impressive elevation was observed 
in severe shock. During recovery, plasma IL-IRa rapidly 
declined within 1 to 2 days (Fig 3), followed by a more 
sustained and moderate elevation in shock patients. In 5 
(36%) of the 14 shock patients who had more than one 
sample within the first 6 hours, IL-IRa decreased directly 
after admission, whereas in the remaining 64%, the decrease 
was preceded by an initial increase. There was no effect of 
PEBE on the IL-1 Ra pattern. After 4 to 5 days, those patients 
who experienced a second febrile episode coinciding with a 
rash and/or sterile reactive arthritis, had again an increase 
of IL-1 Ra. The pattern of IL-1 Ra in CSF was similar to that 
of IL-1/?, with the highest values in meningitis (group A) 
and the lowest values in shock patients without meningitis 
(group C).
In contrast to IL-1 ¡3 and IL-IRa, plasma IL-lsRII concen­
trations at admission did not differ significantly between 
groups A, B and C, and were approximately 25 ng/mL in 
all groups. IL-lsRII transiently decreased during PEBE ses­
sions, especially at day 2 when IL-lsRII concentrations were 
high (>  100 ng/mL). Most remarkably, IL-lsRII behaved 
completely different from IL-1 /? and IL-1 Ra during recovery 
(Fig 4). In 18 of the 20 patients with sequential measure­
ments, IL-lsRII increased during recovery reaching maximal 
concentrations in group A of median 65.6 ng/mL (range, 
35.1 to 107.3) at median 53 hours (range, 26.5 to 92) after 
admission, and in groups B and C of median 145.4 ng/mL 
(range, 48.6 to 224.8; P =  .0009 v group A) at 93.3 hours 
(range, 73 to 107) after admission. This peak coincided w'ith 
the moderate increase in IL-1 ¡3 as shown in Fig 2. In contrast 
to plasma concentrations, CSF concentrations of IL-lsRII 
discriminated well between groups A, B, and C, with the 
highest values in meningitis patients of group A and the 
lowest values in shock patients of group C.
DISCUSSION
In this study, IL-1 (3 and its natural antagonists IL-IRa and 
IL-lsRII were measured in plasma and CSF from patients
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with the prototype disease of acute endotoxin exposure, ie, 
acute meningococcal infections.
Elevated plasma IL-l(3 concentrations were found only in 
patients with severe shock at a very early stage. Within 12 
to 24 hours after admission, plasma IL-1 (3 levels normalized. 
In the majority of these patients (80%). IL-1/? decreased 
rapidly from admission onwards, indicating that IL-1 (3 acti­
vation occurred in a very early preclinical stage of the dis­
ease. In patients with meningitis without shock, IL-1 (3 was 
increased in CSF reflecting compartmentalization of IL-1 (3 
synthesis, a distinctive characteristic of meningococcal in­
fections.6'8,32
In one of our earlier studies, we reported an increase in 
plasma IL-1 (3 concentrations during recovery of meningo­
coccal infections, between 45 and 118 hours after admis­
sion.3, In that study IL-1 (3 was measured in chloro­
form-extracted samples using a slightly different R IA . '4 In 
subsequent measurements, using the D 10-cel 1 bioassay and 
other immunochemical assays, we were unable to substanti­
ate this observation. In the present study, an improved and 
adapted RIA was used.’1 It now appears that, during recovery 
IL-1 (3 increased only slightly (Fig 2), and that this increase 
could be explained by interference of high IL-lsRII concen­
trations. This observation underscores once again the impact 
of soluble cytokine receptors on the measurement of the 
ligand cytokine.22,35,36
Elevated plasma IL-IRa concentrations are found after 
various physical and infectious stimuli.31,37'39 Like IL-6, IL- 
IRa can be considered an easy and reliable indicator of 
activation of the cytokine network.12 In the present study, 
IL-1 Ra was increased at admission in all shock and nonshock 
patients. However, in patients with severe shock, very high 
plasma concentrations were present (median value for fatali­
ties 250.000 pg/mL, range 73,500 to 805,000). O f the shock 
patients, 64% had a short increase of IL-1 Ra after admission 
in contrast to 20% for IL-1 (3 (P = .04). This supports the 
experimental observation that, after endotoxin infusion, 
plasma IL-1 Ra increases shortly following IL-1/3 synthesis.40 
It also underlines the fact that patients with meningococcal 
sepsis enter the hospital in a very early stage of cytokine 
activation and that apparently the devastating pathophysio­
logical derangement occurs within a few hours after the first 
clinical signs and symptoms. As expected. IL-1 Ra accumula­
tion in patients with meningitis without shock occurred 
merely in the subarachnoid space.
Remarkably, the pattern of plasma IL-lsRII was entirely 
different from that of IL-1 (3 and IL-IRa. Both upregulation 
of the “ decoy" receptor IL-1 RII and shedding of this recep­
tor are antiinflammatory processes. Shed IL-1 RII has even 
stronger antiinflammatory potencies than cell-bound IL- 
1 RII, because as compared to IL-IRa, shed receptors bind 
IL-1 (3 with higher affinity.23 Short-lasting studies in humans 
after endotoxin infusion failed to show increased plasma IL- 
lsRII levels.41,42 However, during sepsis and after steroid 
therapy, IL-1 RII mRNA is found to be upregulated and in­
creased densities of cell-bound IL-1 RII on neutrophils are 
measured.20,43"46 Reportedly, during sepsis plasma levels of 
IL-lsRII are only moderately elevated.2<1-42 Our findings are 
in agreement with these observations although we measured
equally increased IL-lsRII plasma concentrations at admis­
sion in patients without or with shock. However, in contrast 
to previous studies in septic patients, we observed a gradual 
increase of IL-lsRII during recovery, reaching maximum 
levels 3 to 4 days after IL-1 (3 activation and 1 to 2 days 
after subsidence of plasma IL-IRa.
Currently, the mechanism of this intriguing pattern is un­
clear. Several factors may have influenced this pattern. Me­
ningococcal sepsis is characterized by massive complement 
activation.47,48 and reportedly, C5a is a potent inducer of IL- 
1RII release from neutrophils.49 However, the major differ­
ence between the present study and previous studies in hu­
man sepsis26,42 is that all patients in the present study received 
dexamethasone. Dexamethasone in vitro stimulates IL-lsRII 
mRNA expression and increases the density of the cell- 
bound receptor.43'46 Lipopolysaccharide (LPS) alone is un­
able to affect IL-1 RII synthesis.50 However, as was recently 
shown/'0 the combination of LPS with dexamethasone in­
duces substantial shedding of IL-lsRII in in vitro experi­
ments. Our clinical data support such a synergistic effect 
of dexamethasone, and suggest that the magnitude of the 
antiinflammatory action of dexamethasone depends on the 
severity of the initial inflammatory signal. In the present 
study, nonshock and shock patients received equal doses of 
dexamethasone; however, the highest IL-lsRII concentra­
tions were found in shock patients of groups B and C, who 
reportedly display the highest levels of endotoxemia and 
complement-activation.2,12,47,48
A second remarkable observation in the present study is 
that, unlike the concentration of IL-lsRII in plasma, the 
concentration in CSF parallels that of IL-1/? and IL-IRa, 
with the highest concentration in meningitis patients. Thus, 
cytokine activation and regulation in the CSF-compartment 
in meningococcal meningitis is not a mere copy of the gener­
alized cytokine activation in meningococcal sepsis.5'8 It is 
tempting to speculate that IL-lsRII in the CSF-compartment 
originates from the activated neutrophils that have invaded 
this extravascular space.
In previous studies, we have shown that TNF soluble re­
ceptors are increased and IL-6sR is decreased early in menin­
gococcal infections.9,12,14 We now show that IL-1/? activity 
is modulated in a more complex fashion. Systemic IL-1 ac­
tivity is mitigated by IL-1 Ra at an early stage of the infection 
and by IL-lsRII at a later stage, whereas in the subarachnoid 
space, both antagonists are increased simultaneously early 
during the infection.
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